A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The overarching purpose of this study is to determine if the mainstay chemotherapeutic
regimens represented by several genotoxic agents including but not limited to
Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and Methotrexate (CDEFM), in the
format of either a single agent or combinations are safe, tolerable, and effective in the
treatment of patients with infiltrating ductal carcinoma of breast.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
China-Japan Union Hospital, Jilin University Ganzhou City People's Hospital Shanghai 10th People's Hospital